Please provide your email address to receive an email when new articles are posted on . Recent findings from the ACCORD trial demonstrated that intensive glucose control to target 6% increased the ...
We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs ...
The main findings of the ADVANCE trial included a 14% reduction in major microvascular events with intensive therapy that was primarily due to a reduction in the incidence of nephropathy (ie, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results